Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegaspargase + ifosfamide + dexamethasone + etoposide
- Development stage
- Unknown
- Lead developer
- Union Hospital of Huazhong University of Science and Technology
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Intramuscular
01
Overview
The P-IE regimen is a combination chemotherapy protocol consisting of pegaspargase, ifosfamide, dexamethasone, and etoposide. It is primarily investigated and used for the treatment of extranodal natural killer/T-cell lymphoma (ENKTL), a rare and aggressive subtype of non-Hodgkin lymphoma. The regimen leverages the unique sensitivity of NK/T-cell lymphoma cells to L-asparaginase (delivered here as the long-acting pegaspargase), which depletes asparagine, an essential amino acid for these tumor cells. Ifosfamide acts as an alkylating agent, etoposide inhibits topoisomerase II to induce DNA breaks, and dexamethasone provides lymphocytolytic effects and reduces inflammation. This combination has been studied by institutions like Union Hospital, Tongji Medical College, to improve outcomes in patients with newly diagnosed or relapsed/refractory ENKTL.
- Other names
- P-IE regimenP-IVE regimen
02
Targets
GR (Glucocorticoid receptor)DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on pegaspargase + ifosfamide + dexamethasone + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegaspargase + ifosfamide + dexamethasone + etoposide.